Stoke Therapeutics (STOK) EBT Margin (2022 - 2026)
Stoke Therapeutics (STOK) posted quarterly EBT Margin of 802.75% for Q1 2026, down 87474.0% year-over-year from N/an in Q1 2025, and up 81.97% quarter-over-quarter from 4453.35% in Q4 2025.
Powered by 
Analysis
Stoke Therapeutics (STOK) EBT Margin (2022 - 2026) Analysis & Trends
Stoke Therapeutics' EBT Margin history runs 5 years deep, the most recent figure standing at 802.75% for Q1 2026.
- In Q1 2026, EBT Margin fell 87474.0% year-over-year to 802.75%; the TTM figure through Mar 2026 stood at 547.22% (down 57199.0% YoY), while the FY2025 annual figure was 110.77%, up 22276.0% from the prior year.
- EBT Margin for Q1 2026 stood at 802.75%, up from 4453.35% in the prior quarter.
- The five-year high for EBT Margin was 71.99% in Q1 2025, with the low at 5809.03% in Q4 2023.
- The 5-year median for EBT Margin is 802.75% (2026), against an average of 1339.78%.
- The sharpest annual moves came in 2024 and 2025: EBT Margin surged 574384 bps in 2024, then slumped 438816 bps in 2025.
- Stoke Therapeutics' EBT Margin stood at 3811.14% in 2022, then tumbled by 52 bps to 5809.03% in 2023, then soared by 99 bps to 65.19% in 2024, then plunged by 6731 bps to 4453.35% in 2025, then jumped by 82 bps to 802.75% in 2026.
- Business Quant data shows STOK's EBT Margin at 802.75% in Q1 2026, 4453.35% in Q4 2025, and 372.7% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 12.09% |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -2.67% |
| 10 | Stoke Therapeutics | 1.96 Bn | 1.66 Bn | - | -660.78% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -660.78% |
| Mar 31, 2026 | -802.75% |
| Dec 31, 2025 | -4,124.39% |
| Sep 30, 2025 | -372.70% |
| Jun 30, 2025 | -169.96% |
| Mar 31, 2025 | 71.99% |
| Dec 31, 2024 | -47.24% |
| Sep 30, 2024 | -540.05% |
| Jun 30, 2024 | -531.88% |
| Mar 31, 2024 | -625.57% |
| Dec 31, 2023 | -963.56% |
| Sep 30, 2023 | -743.14% |
| Jun 30, 2023 | -1,331.84% |
| Mar 31, 2023 | -468.03% |
| Dec 31, 2022 | -786.32% |
| Sep 30, 2022 | -900.28% |
| Jun 30, 2022 | -799.44% |
| Mar 31, 2022 | -843.70% |